Table of Contents
Conventional mRNA therapeutics typically last about a day in the body before they degrade – driving repeat dosing, cost and tolerability burdens that limit how many patients can ever access them.
Circular RNA is roughly an order of magnitude more stable than linear mRNA, extending expression of a therapeutic protein from one day to about a week and unlocking dramatically lower dosing of AAV gene therapies.
Circio Holding ASA (OSE:CRNA) has built a differentiated angle on circular RNA – rather than making the RNA as a finished drug, the company designs DNA expression systems that teach the patient's own cells to produce circular RNA in place of linear mRNA. The technology is being applied first to AAV gene therapy, where Circio's recent ASGCT 2026 data supports substantial dose reduction with the same or better therapeutic protein expression. After two successful 2026 fundraises, the company now has financial visibility well into 2030 to scale its circVec platform and progress big-pharma partnership discussions.
At Meeting on the Med 2026, reporting for Onyx, Federico Citterich sat down with Victor Levitsky to find out more.
A special thanks to our Onyx Live sponsors:
Cellares - delivering cell therapy manufacturing excellence at scale across a global network of IDMO smart factories https://www.cellares.com/
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
Comments